NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) is proud to announce that its Founder and Executive Chairman of the MMRF Board of Directors, Kathy Giusti, has been named to the 2014 PharmaVOICE 100 list for her tireless patient advocacy and dedication to advancing a cure. PharmaVOICE describes the annual list as “Inspirational individuals recognized for their positive contributions to the life-sciences industry.” Giusti was previously named to the list in 2009 for breaking down industry barriers.
As described in the PharmaVOICE 100 issue, “Kathy Giusti has been inspiring patients and the research community since she first took that powerful and visionary step. Her and MMRF’s success has been built on three cornerstones: setting the vision and plan; hiring the talented people; and building a strong collaborative community.”
Longtime member of the MMRF Board of Directors, Meryl Zausner, Executive Vice President and Chief Financial Officer of Novartis Corporation, was also recognized as a 2014 PharmaVOICE 100 honoree for her work in empowering women in the industry. Zausner and Giusti share an additional accolade of both being previous Healthcare Businesswomen’s Association Women of the Year honorees.
“This is a well-deserved honor for both Kathy and Meryl,” said Walter M. Capone, President and Chief Executive Officer of the MMRF. “Their leadership, commitment and advocacy has enabled the tremendous successes of the MMRF and will ensure our continued focus on speed, innovation and results for patients.”
PharmaVOICE states that honorees are nominated by PharmaVOICE readers and are selected based on how they have inspired peers, affected positive change and given back to their communities.
About the Multiple Myeloma Research Foundation (MMRF) The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised $250 million since its inception and directs nearly 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.